Our October Newsletter Highlights: 🔹 Scientific poster accepted at AACR Ovarian Cancer Conference 🔹 Strategic partnership signed with Prestige Biopharma for pancreatic cancer 🔹 Imagion
We are continuing the momentum from our positive phase 1 trial results and are pleased to have recently released our latest updates in our April
We are pleased to provide our investors with our April 2022 Investor Newsletter. In this edition, our Chief Financial Officer, Geoff Hollis, gives a recap
We are pleased to provide our investors with our December 2021 Investor Newsletter. In this edition, our Executive Director and CEO Bob Proulx gives an
Imagion Biosystems is pleased to provide its investors with its September 2021 Investor Newsletter. The newsletter details recent new company developments and activities, including: Message
Imagion Biosystems is pleased to provide its investors with its March 2021 Investor Newsletter. The newsletter details recent new company developments and activities, including: Message
Imagion Biosystems is pleased to provide its investors with its December 2020 Investor Newsletter. The newsletter details recent new company developments and activities including: Message from
Imagion Biosystems Limited is pleased to provide investors with its May 2020 Investor Newsletter. The newsletter details recent key company developments and activities including: Message
In this issue: FDA “Breakthrough Device Designation” Tox Study Completion WMIC 2019 Poster Q&A with Bob Proulx Read the issue.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance